178 related articles for article (PubMed ID: 6788045)
1. [Factor VIII concentrate, highly purified and heated in solution (author's transl)].
Heimburger N; Schwinn H; Gratz P; Lüben G; Kumpe G; Herchenhan B
Arzneimittelforschung; 1981; 31(4):619-22. PubMed ID: 6788045
[TBL] [Abstract][Full Text] [Related]
2. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
3. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
4. Severely heated therapeutic factor VIII concentrate of high specific activity.
Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
[TBL] [Abstract][Full Text] [Related]
5. Modified glycine precipitation technique for the preparation of factor VIII concentrate of high purity and high stability.
Brodniewicz-Proba T; Beauregard D
Vox Sang; 1987; 52(1-2):10-4. PubMed ID: 3111087
[TBL] [Abstract][Full Text] [Related]
6. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII concentrate from cold sterilized human plasma.
Stephan W; Prince AM; Kotitschke R
Dev Biol Stand; 1983; 54():491-5. PubMed ID: 6418593
[TBL] [Abstract][Full Text] [Related]
9. Development and small-scale production of a severely heated factor VIII concentrate.
Knevelman A; de Wit HJ; Potstra P; vd Does JA
Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
Austen DE; Smith JK
Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
[TBL] [Abstract][Full Text] [Related]
11. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
Mason EC; Pepper DS; Griffin B
Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
[TBL] [Abstract][Full Text] [Related]
12. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
13. [Isolation and some properties of factor VIII (antihemophilic factor)].
Bykowska K; Lopaciuk S; Michalski R
Acta Haematol Pol; 1976 OCT-DEC; 7(4):283-92. PubMed ID: 998139
[TBL] [Abstract][Full Text] [Related]
14. Studies on the procurement of coagulation factor VIII: selective precipitation of factor VIII with hydrophilic polymers.
Farrugia A; Griffin B; Pepper D; Prowse C
Thromb Haemost; 1984 Jul; 51(3):338-42. PubMed ID: 6437004
[TBL] [Abstract][Full Text] [Related]
15. Rabbit antibodies against the procoagulant activity (VIII:C) of human factor VIII. Some theoretical and practical considerations on the human factor VIII molecule using heterologous antibodies.
Tran TH; Marbet GA; Duckert F
Thromb Haemost; 1981 Dec; 46(4):699-705. PubMed ID: 6800051
[TBL] [Abstract][Full Text] [Related]
16. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
[TBL] [Abstract][Full Text] [Related]
17. [Comparative protein chemistry studies on Factor VIII concentrates].
Kienast K; Trobisch H
Arzneimittelforschung; 1984; 34(8):895-900. PubMed ID: 6437415
[TBL] [Abstract][Full Text] [Related]
18. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
19. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of human factor VIII. III. Transitions between forms of factor VIII present in cryoprecipitate and in cryosupernatant plasma.
Over J; Bouma BN; Sixma JJ; Bolhuis PA; Vlooswijk RA
J Lab Clin Med; 1980 Mar; 95(3):323-34. PubMed ID: 7354239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
